Study Confirms Effectiveness Of Bivalent COVID-19 Vaccine
A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the..
Eurasia Review
Oxford–AstraZeneca COVID-19 vaccine
Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
0 shares
5 views